SCHEMBL4492756

SCHEMBL4492756

COc1ccc2cc(C(=O)O)c(NCCc3cccc(Cl)c3)nc2c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CSNK2A2 P19784 4/20 0.48
CSNK2A1 P68400 4/20 0.48
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
GFER P55789 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
AKR1C3 P42330 1/20 0.44
AKR1C2 P52895 1/20 0.44
CSNK1D P48730 1/20 0.44
MAOB P27338 3/20 0.44
ADRB1 P08588 1/20 0.43
ADRB3 P13945 1/20 0.43
APEX1 P27695 1/20 0.43
CNR1 P21554 1/20 0.42
TACR3 P29371 1/20 0.42
GSR P00390 1/20 0.42
LCK P06239 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4492686 0.92 CSNK2A2 (0.55) MEN1KMT2ACSNK2A2CSNK2A1AKR1C3
SCHEMBL4501469 0.90 APEX1 (0.49) MEN1KMT2ALMNAHPGDGFER
SCHEMBL4488036 0.90 TACR3 (0.51) MEN1KMT2ACSNK2A2CSNK2A1SMN1; SMN2
SCHEMBL4480962 0.88 CSNK2A2 (0.48) MEN1KMT2ACSNK2A2CSNK2A1MAOB
SCHEMBL4497855 0.86 PTGDR (0.51) MEN1KMT2ACSNK2A2CSNK2A1HPGD
SCHEMBL4484055 0.84 CSNK2A2 (0.52) MEN1KMT2ACSNK2A2CSNK2A1HPGD
SCHEMBL4487805 0.84 NFKB1 (0.48) MEN1KMT2ACSNK2A2CSNK2A1SMN1; SMN2
SCHEMBL4493553 0.84 KMT2A (0.57) MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL4478359 0.83 PTGDR (0.46) MEN1KMT2ACSNK2A2CSNK2A1HPGD
SCHEMBL4486308 0.83 PGK1 (0.50) MEN1KMT2ACSNK2A2CSNK2A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US claimed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP claimed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US claimed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP claimed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO claimed
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US disclosed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP disclosed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US disclosed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP disclosed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106058-A1 Chemical compounds YARS1, DAPK3, NEK3 MEN1 2541/4885KMT2A 3192/4885CSNK2A2 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.